AUGPLAT 500MCG INJECTION

Before taking AUGPLAT 500MCG INJECTION, it is important to inform your physician about any liver problems, history of cancer, recent surgeries, smoking habits, and the use of birth control pills. These factors may affect the safety and effectiveness of the medication, and your physician needs to be aware of them.

The most common side effects of AUGPLAT 500MCG INJECTION include headache and respiratory tract infections. However, side effects can vary from person to person. If you experience any concerning side effects or have any concerns, it is advisable to consult your physician.

AUGPLAT 500MCG INJECTION is administered through subcutaneous injections (under the skin). Your physician will provide the specific dosing and administration instructions.

AUGPLAT 500MCG INJECTION works by stimulating the production of platelets in the bone marrow. It binds to and activates the thrombopoietin receptor, promoting platelet development and maturation. This helps to increase the platelet count in individuals with ITP.

AUGPLAT 500MCG INJECTION is approved for use in adults and children aged 18 years and over with immune primary thrombocytopenia (ITP) when other treatments are ineffective. The pediatrician will determine the dosing and administration.

It is important to inform your doctor about all prescription and non-prescription medications, vitamins, and herbal supplements you are taking before starting AUGPLAT 500MCG INJECTION. Your doctor can check for potential interactions.

Since AUGPLAT 500MCG INJECTION affects platelet production, it is essential to take precautions to avoid injuries and bleeding. Be cautious when engaging in activities that may increase your risk of injury, and report any unusual bleeding or bruising to your physician.

The active ingredient in AUGPLAT 500MCG INJECTION is ROMIPLOSTIM.

AUGPLAT 500MCG INJECTION is primarily prescribed for certain blood disorders, specifically conditions involving low platelet counts.

Yes, AUGPLAT 500MCG INJECTION is approved for use in adults and children aged 18 years and over with immune primary thrombocytopenia (ITP) when other treatments have not been effective.